Comparative safety, pharmacokinetics, and off-target assessment of 1,1-bis(3'-indolyl)-1-(<i>p</i>-chlorophenyl) methane in mouse and dog: implications for therapeutic development.

ABSTRACT: The modified phytochemical derivative, 1,1-bis(3'-indolyl)-1-(p-chlorophenyl) methane (C-DIM12), has been identified as a potential therapeutic platform based on its capacity to improve disease outcomes in models of neurodegeneration and cancer. However, comprehensive safety studies investigating pathology and off-target binding have not been conducted. To address this, we administered C-DIM12 orogastrically to outbred male CD-1 mice for 7 days (50 mg/kg/day, 200 mg/kg/day, and 300 mg/kg/day) and investigated changes in hematology, clinical chemistry, and whole-body tissue pathology. We also delivered a single dose of C-DIM12 (1 mg/kg, 5 mg/kg, 25 mg/kg, 100 mg/kg, 300 mg/kg, 1,000 mg/kg) orogastrically to male and female beagle dogs and investigated hematology and clinical chemistr

SUBMITTER: Rocha SM 

PROVIDER: S-EPMC11033559 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature